IVPatient weighing >12 kg Recommended dose: 0.8 mg/kg as 2-hr infusion via central venous catheter every 6 hr for 4 consecutive days for total of 16 doses (Days -7, -6, -5 & -4) in combination w/ cyclophosphamide 60 mg/kg as 1-hr IV infusion on each of 2 days beginning no sooner than 6 hr following 16th dose of Busulfan (Days -3 & -2). Premed w/ anticonvulsants eg, benzodiazepines, phenytoin, valproic acid or levetiracetam 12 hr prior to Busulfan to 24 hr after the last dose of Busulfan. Administer antiemetics prior to 1st dose of Busulfan.
Prolonged myelosuppression; seizures; bronchopulmonary dysplasia w/ pulmonary fibrosis; cellular dysplasia. Increased risk of developing hepatic veno-occlusive disease in patients who have received prior RT, ≥3 cycles of chemotherapy, or prior progenitor cell transplant. Patient w/ history of seizure or head trauma or who are receiving other potentially epileptogenic drugs. Monitor CBC including WBC differentials & quantitative platelet counts daily during treatment & until engraftment is demonstrated; serum transaminases, alkaline phosphatase & bilirubin daily through BMT Day +28 to detect hepatotoxicity. Initiate anticonvulsant prophylactic therapy prior to treatment. Renal & hepatic impairment. Potential risk to fetus. Ovarian suppression & amenorrhea in premenopausal women undergoing chronic, low-dose therapy for CML. Sterility, azoospermia, & testicular atrophy in men. Men & women of reproductive potential should use effective contraception during & after treatment. Discontinue lactation during treatment. Cardiac tamponade in ped patients w/ thalassemia.
Sign Out
